Skip to content
AnalystLens

Leidos Holdings Quarterly Report for Q1 Ended Mar 29, 2024

Filing Date
Filed April 30, 2024
Period End
March 29, 2024
Security
LDOS
One revenue dollarkept$0.07
In the record · 2016–202610-K1210-Q338-K130

LDOS filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 130 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Aug ’17Aug ’17
  2. Leadership change8-K · Mar ’20Mar ’20
  3. Leadership change8-K · Feb ’22Feb ’22
  4. Material agreement8-K · Oct ’26Oct ’26

Summary

Summary of the 10-Q filed April 30, 2024. Cited figures are marked; the original filing is the authoritative source.

Leidos Holdings, Inc. reported first-quarter 2024 revenues of $3,975 milliona, up 7.5% from $3,699 million in the prior-year quarter.

Operating income rose to $415 millionb from $265 million, lifting operating margin to 10.4% from 7.2%. Net income attributable to Leidos common stockholders was $284 million, compared with $162 million, and diluted EPS was $2.07 versus $1.17. The filing attributes the growth mainly to higher volumes and program wins, with Health & Civil the largest contributor.

Health & Civil revenue grew 18.9% to $1,199 millionc, and its operating income more than doubled to $222 million, reflecting higher managed health services volumes and favorable business mix. The company's balance sheet and liquidity remained stable. Cash and cash equivalents were $633 million, outstanding debt was $4.7 billion, and there were no borrowings under the $1 billion revolving facility.

Operating cash flow was $63 milliond, compared with negative $98 million a year earlier, mainly due to lower tax payments. The company returned capital through $53 million in dividends and open market repurchases of about $150 million. Total backlog was $36.6 billion, net bookings were an estimated $3.7 billion, and remaining performance obligations were $14.3 billion.

The filing also discloses ongoing legal and regulatory matters. Leidos is conducting an internal investigation into international operations that may have violated the FCPA, has self-reported to the DOJ and SEC, and cannot anticipate the timing or outcome.

A separate DOJ Antitrust Division grand jury subpoena relates to three U.S. government procurements, and the company states it cannot reasonably estimate potential penalties. The VirnetX Apple II patent case concluded on February 20, 2024, with no proceeds received by Leidos.

Key Highlights

  1. Revenue rose 7.5% to $3,975 million, and operating income increased 56.6% to $415 million, with operating margin expanding to 10.4% from 7.2%.
  2. Health & Civil revenue grew 18.9% to $1,199 million, and operating income rose to $222 million from $113 million, with margin at 18.5% versus 11.2%.
  3. Diluted EPS was $2.07 versus $1.17, and net income attributable to Leidos common stockholders was $284 million versus $162 million.
  4. Operating cash flow was $63 million, compared with negative $98 million in the prior-year quarter, primarily due to lower tax payments.
  5. Total backlog was $36.6 billion, with net bookings of an estimated $3.7 billion, and remaining performance obligations were $14.3 billion as of March 29, 2024.
  6. Cash of $633 million and debt of $4.7 billion were reported, with no borrowings under the $1 billion revolving facility.
  7. The VirnetX Apple II patent case closed on February 20, 2024, with no proceeds received by Leidos, while FCPA and antitrust investigations remain ongoing.

Follow one dollar

Of each $1.00 of revenue in Q1 FY2025, Leidos Holdings kept $0.07.

  1. Revenue$3.95B100.0%
  2. Cost of revenue−$3.34B84.5%
  3. Gross profit$614.0M15.5%
  4. Operating costs−$199.0M5.0%
  5. Operating income$415.0M10.5%
  6. Interest, other & tax−$131.0M3.3%
  7. Net income$284.0M7.2%
Computed from 10-QQ1 FY2025filed April 30, 2024Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Financial Statements

Q1 FY2025 against Q1 FY2024

Line itemQ1 FY2025Q1 FY2024Change
Revenue$3.95B$3.68B+7.4%
Cost of Revenue$3.34B$3.20B+4.2%
Gross Profit$614.00M$475.00M+29.3%
SG&A Expenses$226.00M$233.00M−3.0%
Operating Income$415.00M$265.00M+56.6%
Net Income$284.00M$162.00M+75.3%
EPS (Basic)$2.09$1.18+77.1%
EPS (Diluted)$2.07$1.17+76.9%
Shares Outstanding (Basic)136.00M137.00M−0.7%
Shares Outstanding (Diluted)137.00M138.00M−0.7%

Frequently Asked Questions

  1. What drove the increase in operating income this quarter?

    Operating income rose to $415 million from $265 million. The filing attributes the segment gains mainly to a net increase in volumes and favorable business mix in the managed health services business within Health & Civil, along with net volume increases in National Security and Digital and Commercial & International. Corporate operating loss increased to $37 million from $29 million, primarily due to higher general and administrative expenses.

  2. How much of Leidos's revenue comes from the U.S. government?

    The filing states that approximately 87% of total revenues in both the current and prior-year quarters came from contracts with the U.S. government. International sales represented approximately 8% of total revenues in both periods. Leidos notes that its performance is therefore affected by overall U.S. government spending priorities.

  3. What legal or regulatory risks does the filing disclose?

    Leidos is conducting an internal investigation, overseen by an independent Board committee, into conduct at its international operations that may have violated the FCPA. The company self-reported to the DOJ and SEC and received a grand jury subpoena in September 2022. A separate DOJ Antitrust Division subpoena from August 2022 concerns three U.S. government procurements. The company states it cannot anticipate the outcome of these investigations, and violations could result in criminal and civil sanctions.

  4. How did cash flow and capital returns change?

    Net cash provided by operating activities was $63 million, an increase of $161 million from the prior year, largely due to lower tax payments. Net cash used in financing activities was $228 million, including $53 million in dividends and about $150 million in open market stock repurchases. The company paid dividends of $0.38 per share during the quarter.

  5. What is the status of the VirnetX litigation?

    On February 20, 2024, the U.S. Supreme Court denied VirnetX's petition for a writ of certiorari, which closed the Apple II case. As a result, Leidos received no proceeds from the case. Earlier, the Federal Circuit had found certain patent claims unpatentable and vacated the district court judgment.